Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification
Katarzyna Borys(Essen University Hospital), Felix Nensa(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Eugen Malamutmann(Essen University Hospital), Benedikt M. Schaarschmidt(Essen University Hospital), Jens Kleesiek(Essen University Hospital), René Hosch(Essen University Hospital), Stephan Lang(Essen University Hospital), Sebastian Bauer(Science for Life Laboratory), Johannes Haubold(Essen University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Sara Schramm(University of Duisburg-Essen), Servet Bölükbas(Ruhrlandklinik), Rainer Kimmig(Essen University Hospital), Arzu Oezcelik(Essen University Hospital), Lale Umutlu(Essen University Hospital), Moon Kim(Essen University Hospital), Anja Merkel‐Jens(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Christoph M. Friedrich(Fraunhofer Institute for Algorithms and Scientific Computing), Giulia Baldini(Essen University Hospital), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Martin Stuschke(Essen University Hospital), Jens T. Siveke(German Cancer Research Center), Boris Hadaschik(Essen University Hospital), Lennard Kroll(University Hospital of Basel), Andreas Stang(Boston University), Julius Keyl(Essen University Hospital), Marcel Wiesweg(Essen University Hospital), Nicolas Coquelet(Institut Jules Bordet), Judith Kohnke(Essen University Hospital), Riccardo De Angelis(Université Libre de Bruxelles), Ken Herrmann(Essen University Hospital), Martin Schuler(National Center for Tumor Diseases), Michael Forsting(Essen University Hospital), Viktor Gruenwald(Medizinische Hochschule Hannover), Jürgen Treckmann(Essen University Hospital), Kévin Brou Boni(Université Libre de Bruxelles), Stefan Kasper(Essen University Hospital)
Cited by 8
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k